Pay in 4 interest-free payments of $6.43 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Apitegromab, a selective antimyostatin monoclonal antibody targeting muscle preservation, added to tirzepatide reduced muscle loss by ~55% over 24 weeks without affecting overall weight loss in the phase 2 EMBRAZE trial
Management should be approached holistically, addressing nutritional adequacy, general wellbeing, and any identifiable underlying causes
Continued authorization: Many states require evidence of ongoing weight loss (typically 5% or more body weight loss within 12 to 16 weeks) to continue coverage Tips for Successful Prior Authorization Document BMI, comorbidities, and lifestyle counseling at every patient visit, not just the visit where you submit the PA Include specific, detailed language about failed interventions in your clinical notes Submit the PA with complete documentation on the first attempt to avoid delays from requests for additional information Use peer-reviewed clinical trial data (STEP, SURMOUNT) to support your letter of medical necessity Track PA timelines and follow up proactively rather than waiting for automatic denial at the deadline How to Appeal a Medicaid Denial for Weight Loss Medication When Medicaid does not cover weight loss shots on the first attempt, an appeal is often warranted and frequently successful
rival Eli Lilly had moved to aggressively cut prices on their GLP-1 weight-loss drugs, Hims announced plans to offer a compounded oral semaglutide pill for $49 - a version of Novo Nordisk's new Wegovy pill launched in January
